Enhanced Bacillus Calmette-Guerin (BCG) and Antigen Presenting Cells for Bladder Cancer Treatment
Legal Citation
Summary of the Inventive Concept
The inventive concept disclosed herein relates to novel improvements and enhancements to the original Bacillus Calmette-Guerin (BCG) and antigen presenting cells composition for treating bladder cancer, focusing on direct improvements and enhancements to make the original inventive concept better, faster, safer, or more efficient.
Background and Problem Solved
The original patent disclosed the use of BCG and antigen presenting cells for treating bladder cancer. However, the original composition had limitations, such as limited efficacy in elderly patients, lack of personalized treatment options, and limited immune response monitoring capabilities. The new inventive concept addresses these limitations by introducing novel formulations, devices, and methods that enhance the immune response, provide personalized treatment options, and enable effective immune response monitoring.
Detailed Description of the Inventive Concept
The new inventive concept comprises five key aspects: (1) a method for treating bladder cancer in elderly patients by administering a vaccine composition with enhanced immune response; (2) a system for personalized bladder cancer treatment using a device for isolating antigen presenting cells and a processor for determining optimal IL-15:IL-15Rα fusion protein complex dosage; (3) a vaccine composition with genetically modified antigen presenting cells expressing a bladder cancer-specific antigen; (4) a method for monitoring immune response to bladder cancer treatment by analyzing urine samples or bladder mucosa for immune cell activation markers; and (5) a kit for preparing a vaccine composition with an instruction manual for formulating the vaccine composition with an IL-15:IL-15Rα fusion protein complex. These aspects work together to provide a more effective, personalized, and efficient treatment for bladder cancer.
Novelty and Inventive Step
The new inventive concept is novel and non-obvious compared to the original patent, as it introduces new formulations, devices, and methods that address the limitations of the original composition. The inventive step lies in the combination of these new aspects, which provide a more comprehensive and effective treatment for bladder cancer.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include using different types of antigen presenting cells, modifying the IL-15:IL-15Rα fusion protein complex, or incorporating additional immune response enhancers. Variations of the system for personalized treatment could include using different devices or processors for determining optimal dosage.
Potential Commercial Applications and Market
The new inventive concept has significant commercial potential in the bladder cancer treatment market, which is expected to grow significantly in the coming years. The inventive concept's focus on personalized treatment, enhanced immune response, and effective immune response monitoring makes it an attractive solution for patients, clinicians, and pharmaceutical companies.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/04 |
| A | A61 | A61K35/15 |
| A | A61 | A61K39/00114 |
| A | A61 | A61K39/001119 |
| A | A61 | A61K39/39 |
| A | A61 | A61K2039/515 |
| A | A61 | A61K2039/585 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Immunotherapy and cancer treatment, specifically focusing on bladder cancer immunotherapeutic approaches involving antigen presenting cells and cytokine complexes. Requires expertise in cellular immunology, cancer biology, and therapeutic protein engineering
Person of Ordinary Skill (PHOSITA) Profile
A researcher or medical professional with advanced degree (PhD/MD) in immunology or oncology, familiar with BCG immunotherapy, cell isolation techniques, cytokine complexes, and personalized cancer treatment strategies
Obviousness Rationale
A PHOSITA would recognize that the PTD represents predictable extensions of the source patent's core immunotherapeutic approach by introducing incremental improvements in patient-specific treatment, cell modification, and immune response monitoring. The variations represent logical combinations of known techniques in immunotherapy that would be apparent to a skilled practitioner seeking to optimize bladder cancer treatment. The disclosed modifications demonstrate standard problem-solving approaches within the field of cancer immunotherapy.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,612 |
|---|---|
| Title | Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer |
| Assignee(s) | NantCell, Inc. |